NMOSD Market Is Expected To Grow During the Forecast Period (2019-2032), DelveInsight

A detailed review of the historical and forecasted NMOSD Market is included in the report, covering drug outreach in the 7MM countries. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global NMOSD market. An all-inclusive account of both the current and emerging therapies for NMOSD, along with the assessment of new therapies, which will have an impact on the current treatment landscape.

NMOSD: An Overview
Neuromyelitis optica spectrum disorder (NMOSD), also known as Devic disease, is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis). Classically, it was felt to be a monophasic illness, consisting of episodes of inflammation of one or both optic nerves and the spinal cord over a short period (days or weeks) but, after the initial episode, no recurrence. It is now recognized that most patients satisfying current criteria for NMOSD experience repeated attacks separated by periods of remission. The interval between attacks may be weeks, months, or years. In its early stages, NMOSD may be confused with multiple sclerosis (MS).

Discover more information about the report- https://www.delveinsight.com/report-store/neuromyelitis-optica-spectrum-disorder-nmosd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key highlights of the NMOSD Market Report
• According to the Orphanet, NMO has a worldwide distribution and an estimated prevalence of 1-2/100,000.
• According to the "National Organization for Rare Disorders", the prevalence of NMOSD is approximately 1-10 per 100,000 individuals and seems to be similar worldwide, although somewhat higher rates have been reported in countries with a higher proportion of individuals of African ancestry.
• As per the National Organization for Rare Disorders, Individuals of any age may be affected, but typically NMOSD especially cases seropositive for AQP4-IgG, occur in late middle-aged women. Women, especially those with AQP4-IgG, are four or five times more likely to be affected than men by the recurring (relapsing) form.

NMOSD Epidemiology Insights
Epidemiological studies of the uncommon disorder Neuromyelitis Optica Spectrum Disorder (NMOSD) may be difficult to interpret because of the evolving nature of diagnostic criteria, differences in the definition and accuracy of NMOSD diagnosis, the completeness of case ascertainment, and variability in assays for the disease‐specific biomarker aquaporin‐4 (AQP4)‐IgG. A sub‐group of patients with the clinical syndrome NMOSD lack detectable AQP4‐IgG and in these cases an accurate diagnosis requires precise diagnostic algorithms and longitudinal follow‐up. Knowledge of NMOSD epidemiology is critical for the appropriate allocation of healthcare resources.

NMOSD Epidemiology Segmentation in the 7MM
• Total Prevalent Cases
• Age-specific Prevalence
• Gender-Specific Prevalence
• Diagnosed Cases

NMOSD Market Insights
Neuromyelitis Optica Spectrum Disorder (NMOSD) is a heterogeneous but well-defined clinical entity, distinct from other neurologic and systemic inflammatory diseases, and treatment is poised for expansion. Treatment of NMO includes both the management of acute attacks and the prevention of future exacerbations. The goal of acute therapy is to minimize irreversible damage and accelerate recovery. Preventative therapy should lower the frequency and severity of future exacerbations.

NMOSD Treatment Market
Symptomatic treatment of immobility, neuropathic pain, spasticity, urinary retention/incontinence, depression, fatigue, and cognitive dysfunction in NMOSD patients has not been adequately studied, especially compared to the numerous studies of immunotherapies to prevent relapses. Even after successful induction of remission, NMOSD patients contend with serious complications of the spinal cord and brainstem and optic nerve damage that limit their quality of life.

For the Symptomatic treatment there are four general classes of pain medications commonly used in NMOSD patients
(1) Anti-epileptic medications (e.g., gabapentin, carbamazepine),
(2) Antispasmodics (e.g., baclofen, tizanidine),
(3) Anti-depressants (e.g., amitript yline, duloxetine), and
(4) Analgesics

NMOSD Market Dynamics
The dynamics of the Neuromyelitis Optica Spectrum Disorder market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecast period of 2020-2030.

NMOSD Market Forecast
To summarize, a better and clear understanding of the pathogenesis of Neuromyelitis Optica Spectrum Disorder (NMOSD) will significantly improve the treatment regimens and development of novel therapies. With this, several companies have started working toward the development of new therapeutic options. The market is expected to experience positive growth in the coming years owing to the already prescribed products along with the launch of distinctive emerging therapies in the coming years.

Request a Sample Copy of the Report- https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

NMOSD Market Size
The market size shall grow during the forecast period owing to the launch of upcoming therapies. The market size is expected to increase at a CAGR of XX during the study period. Expected launch of the pipeline therapies such as BAT4406F, RC18, HBM9161, Satralizumab (US and EU), and others shall fuel the growth of the market during the forecast period, i.e., 2020-2030.

NMOSD Market Outlook
The Neuromyelitis Optica Spectrum Disorder (NMOSD) market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Neuromyelitis Optica Spectrum Disorder (NMOSD) market trends by analyzing the impact of current Neuromyelitis Optica Spectrum Disorder (NMOSD) therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

NMOSD Companies & Therapies
• Soliris: Alexion Pharmaceuticals
• Uplinza: Viela Bio
• BAT4406F: Bio-Thera Solutions
• RC18: RemeGen
• CRD1 / cladribine: Chord Therapeutics, and Several Others

Explore information about the report- https://www.delveinsight.com/report-store/neuromyelitis-optica-spectrum-disorder-nmosd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Executive Summary of NMOSD
3. Competitive Intelligence Analysis for NMOSD
4. NMOSD: Market Overview at a Glance
5. NMOSD: Disease Background and Overview
6. Patient Journey
7. NMOSD Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. NMOSD Unmet Needs
10. Key Endpoints of NMOSD Treatment
11. NMOSD Marketed Products
12. NMOSD Emerging Therapies
13. NMOSD: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of NMOSD
17. KOL Views
18. NMOSD Market Drivers
19. NMOSD Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Get in touch with our Business Development Expert- https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Contact Us
Yash
info@delveinsight.com

About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.